single invest


PanCryos (Denmark) aims to develop a next generation stem cell derived allogenic cell therapy (PanINSULA™) for Type 1 diabetes

PanCryos has been a part of the Accelerace accelerator program, that help startup companies accelerate and scale up their business model and finetune their companies. PanCryos is one of more than 500 companies that Accelerace already have accelerated.

Related startups